ASX-listed Chrysos says its 2025 annual revenue is tracking at the lower end of its A$60-70 million guidance range after posting $16.2m third-quarter sales, up 25% year-on-year.
EBITDA was tracking below the midpoint of the company’s $9-19m guidance range for the year ending June 30, 2025, Chrysos said.
The company said 1.7 million samples analysed in Q3 with its non-chemical PhotonAssay technology was up 57% yoy.
Two further PhotonAssay units contracted with ALS took the number of contracted Chrysos units to 58, with the company deploying five new PhotonAssay units including an initial machine in Namibia and others in the USA and Australia.
“Chrysos remains well-funded to continue PhotonAssay unit growth with $35.1m in cash and $77.1m in undrawn debt available as of 31 March 2025,” the company said.
Chrysos’ share price is up about 8% in the past month, taking the company’s market value to about $456 million.
